检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]南京医科大学第一附属医院内分泌科,南京210029
出 处:《国际内科学杂志》2009年第12期715-717,738,共4页International Journal of Internal Medicine
摘 要:大量的临床研究发现,肥胖程度与甲状腺功能的变化有关,而肥胖与甲状腺功能状态的改变熟因熟果目前尚存争论。肥胖症患者甲状腺功能的变化可能会引起心血管疾病风险的增加和胰岛素抵抗的加重。此外,肥胖症患者罹患结节性甲状腺肿和亚临床甲状腺功能减退的概率也明显上升,肥胖所致的低度炎症状态和内源性激素的分泌增加可能参与了甲状腺局部免疫状态的变化。虽然目前并不推荐甲状腺激素用作肥胖症的治疗,但是甲状腺激素的类似物GC-1为这一设想带来了新的希望。Lots of clinical studies found that obesity was associated with thyroid dysfunction, though the mechanism remains to be determined. Changes of thyroid function in obese patients may increase the risk of cardiovascular disease and insulin resistance. Recent studies have shown that the incidence of nodular goiter and subclinical hypothyroidism was also increased in obesity. The slight inflammatory state induced by obesity and abnormal endogenous hormone secretion may be involved in local immunological alterations in the thyroid gland and lead to thyroid dysfunction and nodular goiter. Although thyroxine is not recommend to treat obesity, its synthetic analogue named GC-1 brings new hope to this design.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.191.28.190